Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia

Bulletin of the National Research Centre

Heba K. Nabih¹ 

[1] Medical Biochemistry Department, Medical Research Division, National Research Centre, P.O. 12622, 33 El Bohouth St. (Former El Tahrir St.), Dokki, Giza, Egypt;

关键词: COVID-19;    Lymphocytopenia;    Immunoglobulins;    Immunotherapy;    Passive immunization;    Convalescent plasma therapy;   

DOI  :  10.1186/s42269-021-00502-4

来源: Springer

【 摘 要 】

BackgroundThe global coronavirus disease 2019 (COVID-19) was announced as pandemic by the World Health Organization (WHO). With the increased number of infected and dead victims daily all over the world, it becomes necessary to stop or overcome its rapid spread.Main bodyAlthough the production of vaccine or even specified effective anti-virus may take about six months to a year, intravenous immunoglobulin (IVIg) may be clinically used as a safe treatment to save and improve the quality of life of patients with a variety of immunodeficiency diseases such as lymphocytopenia, which is a common clinical feature in COVID-19.ConclusionThrough the current review, it was concluded that this passive immunization may promote the immunity to better fight against the virus, so the survival of the patients could be kept longer. The efficacy of immunotherapy with IVIg would be greater if the immune IgG antibodies were collected from convalescent plasma therapy.

【 授权许可】

CC BY